Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

The company may have more catalysts ahead Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game ...